Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78).
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
established
Claim: Liraglutide lowered HbA1c more than albiglutide in a head-to-head phase 3 trial (HARMONY 7)standing
resolved
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J, HARMONY 7 study group
Claim: Albiglutide reduced major cardiovascular events against placebo in type 2 diabetes with cardiovascular disease (Harmony Outcomes)standing
resolved
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators
A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.